• Je něco špatně v tomto záznamu ?

Synthesis and In Vitro Antimycobacterial Activity of Novel N-Arylpiperazines Containing an Ethane-1,2-diyl Connecting Chain

T. Goněc, I. Malík, J. Csöllei, J. Jampílek, J. Stolaříková, I. Solovič, P. Mikuš, S. Keltošová, P. Kollár, J. O'Mahony, A. Coffey,

. 2017 ; 22 (12) : . [pub] 20171130

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18033506

Novel 1-(2-{3-/4-[(alkoxycarbonyl)amino]phenyl}-2-hydroxyethyl)-4-(2-fluorophenyl)-piperazin-1-ium chlorides (alkoxy = methoxy to butoxy; 8a-h) have been designed and synthesized through multistep reactions as a part of on-going research programme focused on finding new antimycobacterials. Lipophilic properties of these compounds were estimated by RP-HPLC using methanol/water mobile phases with a various volume fraction of the organic modifier. The log kw values, which were extrapolated from intercepts of a linear relationship between the logarithm of a retention factor k (log k) and volume fraction of a mobile phase modifier (ϕM), varied from 2.113 (compound 8e) to 2.930 (compound 8h) and indicated relatively high lipophilicity of these salts. Electronic properties of the molecules 8a-h were investigated by evaluation of their UV/Vis spectra. In a next phase of the research, the compounds 8a-h were in vitro screened against M. tuberculosis CNCTC My 331/88 (identical with H37Rv and ATCC 2794), M. kansasii CNCTC My 235/80 (identical with ATCC 12478), a M. kansasii 6 509/96 clinical isolate, M. avium CNCTC My 330/80 (identical with ATCC 25291) and M. avium intracellulare ATCC 13950, respectively, as well as against M. kansasii CIT11/06, M. avium subsp. paratuberculosis CIT03 and M. avium hominissuis CIT10/08 clinical isolates using isoniazid, ethambutol, ofloxacin, ciprofloxacin or pyrazinamide as reference drugs. The tested compounds 8a-h were found to be the most promising against M. tuberculosis; a MIC = 8 μM was observed for the most effective 1-(2-{4-[(butoxycarbonyl)amino]phen-ylphenyl}-2-hydroxyethyl)-4-(2-fluorophenyl)piperazin-1-ium chloride (8h). In addition, all of them showed low (insignificant) in vitro toxicity against a human monocytic leukemia THP-1 cell line, as observed LD50 values > 30 μM indicated. The structure-antimycobacterial activity relationships of the analyzed 8a-h series are also discussed.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033506
003      
CZ-PrNML
005      
20181010124959.0
007      
ta
008      
181008s2017 sz f 000 00|eng||
009      
AR
024    7_
$a 10.3390/molecules22122100 $2 doi
035    __
$a (PubMed)29189762
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Goněc, Tomáš $u Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences in Brno, Palackého 1946/1, Brno CZ-612 42, Czech Republic. gonect@vfu.cz.
245    10
$a Synthesis and In Vitro Antimycobacterial Activity of Novel N-Arylpiperazines Containing an Ethane-1,2-diyl Connecting Chain / $c T. Goněc, I. Malík, J. Csöllei, J. Jampílek, J. Stolaříková, I. Solovič, P. Mikuš, S. Keltošová, P. Kollár, J. O'Mahony, A. Coffey,
520    9_
$a Novel 1-(2-{3-/4-[(alkoxycarbonyl)amino]phenyl}-2-hydroxyethyl)-4-(2-fluorophenyl)-piperazin-1-ium chlorides (alkoxy = methoxy to butoxy; 8a-h) have been designed and synthesized through multistep reactions as a part of on-going research programme focused on finding new antimycobacterials. Lipophilic properties of these compounds were estimated by RP-HPLC using methanol/water mobile phases with a various volume fraction of the organic modifier. The log kw values, which were extrapolated from intercepts of a linear relationship between the logarithm of a retention factor k (log k) and volume fraction of a mobile phase modifier (ϕM), varied from 2.113 (compound 8e) to 2.930 (compound 8h) and indicated relatively high lipophilicity of these salts. Electronic properties of the molecules 8a-h were investigated by evaluation of their UV/Vis spectra. In a next phase of the research, the compounds 8a-h were in vitro screened against M. tuberculosis CNCTC My 331/88 (identical with H37Rv and ATCC 2794), M. kansasii CNCTC My 235/80 (identical with ATCC 12478), a M. kansasii 6 509/96 clinical isolate, M. avium CNCTC My 330/80 (identical with ATCC 25291) and M. avium intracellulare ATCC 13950, respectively, as well as against M. kansasii CIT11/06, M. avium subsp. paratuberculosis CIT03 and M. avium hominissuis CIT10/08 clinical isolates using isoniazid, ethambutol, ofloxacin, ciprofloxacin or pyrazinamide as reference drugs. The tested compounds 8a-h were found to be the most promising against M. tuberculosis; a MIC = 8 μM was observed for the most effective 1-(2-{4-[(butoxycarbonyl)amino]phen-ylphenyl}-2-hydroxyethyl)-4-(2-fluorophenyl)piperazin-1-ium chloride (8h). In addition, all of them showed low (insignificant) in vitro toxicity against a human monocytic leukemia THP-1 cell line, as observed LD50 values > 30 μM indicated. The structure-antimycobacterial activity relationships of the analyzed 8a-h series are also discussed.
650    _2
$a antituberkulotika $x chemická syntéza $x chemie $x farmakologie $7 D000995
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a lidé $7 D006801
650    _2
$a hydrofobní a hydrofilní interakce $7 D057927
650    _2
$a mikrobiální testy citlivosti $7 D008826
650    _2
$a molekulární struktura $7 D015394
650    _2
$a Mycobacterium tuberculosis $x účinky léků $7 D009169
650    _2
$a piperaziny $x chemická syntéza $x chemie $x farmakologie $7 D010879
650    _2
$a spektrální analýza $7 D013057
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
655    _2
$a časopisecké články $7 D016428
700    1_
$a Malík, Ivan $u Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University in Bratislava, Odbojárov 10, Bratislava SK-832 32, Slovakia. malikivan001@gmail.com.
700    1_
$a Csöllei, Jozef $u Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences in Brno, Palackého 1946/1, Brno CZ-612 42, Czech Republic. csolleij@vfu.cz.
700    1_
$a Jampílek, Josef $u Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University in Bratislava, Odbojárov 10, Bratislava SK-832 32, Slovakia. josef.jampilek@gmail.com.
700    1_
$a Stolaříková, Jiřina $u Laboratory for Mycobacterial Diagnostics and Tuberculosis, Regional Institute of Public Health, Partyzánské náměstí 7, Ostrava CZ-702 00, Czech Republic. Jirina.Stolarikova@zu.cz.
700    1_
$a Solovič, Ivan $u Clinic for Tuberculosis and Lung Diseases, National Institute for Tuberculosis, Lung Diseases and Thoracic Surgery, Vyšné Hágy, Vysoké Tatry SK-059 84, Slovakia. solovic@hagy.sk. Department of Public Health, Faculty of Health, Catholic University in Ružomberok, Hrabovská cesta 1A, Ružomberok SK-034 01, Slovakia. solovic@hagy.sk.
700    1_
$a Mikuš, Peter $u Department of Pharmaceutical Analysis and Nuclear Pharmacy, Faculty of Pharmacy, Comenius University in Bratislava, Odbojárov 10, Bratislava SK-832 32, Slovakia. mikus@fpharm.uniba.sk.
700    1_
$a Keltošová, Stanislava $u Department of Human Pharmacology and Toxicology, University of Veterinary and Pharmaceutical Sciences in Brno, Palackého 1946/1, Brno CZ-612 42, Slovakia. keltosovas@vfu.cz.
700    1_
$a Kollár, Peter $u Department of Human Pharmacology and Toxicology, University of Veterinary and Pharmaceutical Sciences in Brno, Palackého 1946/1, Brno CZ-612 42, Slovakia. kollarp@vfu.cz.
700    1_
$a O'Mahony, Jim $u Department of Biological Sciences, Cork Institute of Technology, Bishopstown, Cork T12 P928, UK. jim.omahony@cit.ie.
700    1_
$a Coffey, Aidan $u Department of Biological Sciences, Cork Institute of Technology, Bishopstown, Cork T12 P928, UK. aidan.coffey@cit.ie.
773    0_
$w MED00180394 $t Molecules (Basel, Switzerland) $x 1420-3049 $g Roč. 22, č. 12 (2017)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29189762 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181010125449 $b ABA008
999    __
$a ok $b bmc $g 1340928 $s 1030500
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 22 $c 12 $e 20171130 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
LZP    __
$a Pubmed-20181008

Najít záznam

Citační ukazatele

Možnosti archivace